<DOC>
	<DOCNO>NCT00442780</DOCNO>
	<brief_summary>The main purpose study determine safety BIIB014 well BIIB014 tolerate give different dos patient early-stage Parkinson 's Disease . This study also explore : - How BIIB014 affect give patient early-stage Parkinson 's Disease ( do measuring level BIIB014 blood several different time study ) , - The activity BIIB014 give early Parkinson 's patient ( do perform different Parkinson 's Disease assessments test study ) . Patients enter study randomly assign receive either BIIB014 placebo study blind , neither study doctor know study treatment take .</brief_summary>
	<brief_title>Dose-Finding Safety Study BIIB014 Early-Stage Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>3- ( 4-amino-3-methylbenzyl ) -7- ( 2-furyl ) -3H- ( 1,2,3 ) triazolo ( 4,5-d ) pyrimidine-5-amine</mesh_term>
	<criteria>Must give write informed consent authorization require local law . Must carry diagnosis idiopathic Parkinson 's Disease ( PD ) , without know suspected cause parkinsonism , accord UK Parkinson 's Disease Society Brain Bank Clinical Diagnostic Criteria . Initial diagnosis PD must make within 5 year prior Screening least two follow cardinal sign present : bradykinesia , rest tremor , rigidity , postural instability . Must modify Hoehn &amp; Yahr Stage 1 2.5 ( inclusive ) . Must baseline UPDRS ( Part III ) motor score least 10 . Subjects may receive anticholinergic agent and/or MAOB inhibitor ( stable dose medication least 4 week prior study entry ) must receive PD medication . A Mini Mental State Examination ( MMSE ) score &lt; 26 . History clinical feature consistent atypical parkinsonian syndrome . Any significant nonPD central nervous system disorder . Any significant AXIS I psychiatric disease define Diagnostic Statistical Manual Mental Disorders . History cognitive neuropsychiatric condition . History surgical intervention PD . History LDOPAinduced motor nonmotor complication . History malignancy . History severe allergic anaphylactic reaction drug . Clinically significant renal dysfunction . HbA1c &gt; 7.0 % . Clinically significant baseline ECG . Orthostatic hypotension . Treatment LDOPA/carbidopa LDOPA/benserazide 6 cumulative month anytime since subject 's initial PD diagnosis .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>early Parkinson 's Disease</keyword>
	<keyword>MOBILE</keyword>
	<keyword>BIIB014</keyword>
</DOC>